Drugs / Army Liposome Formulation containing QS-21
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05500417 | Sep 2022 → Jan 2025 | campylobacteriosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Army Liposome Formulation containing QS-21 | “ALFQ (Army Liposome Formulation containing QS-21) is composed of ALF55 (cGMP-manufactured Army Liposome Formulation), QS-21 (purified extracted saponin), and Sorensen's...” NCT05500417 ↗ |
| Known as | ALFQ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05500417 ↗ |
| Modality | Other / unclassified | “ALFQ (Army Liposome Formulation containing QS-21) is composed of ALF55 (cGMP-manufactured Army Liposome Formulation), QS-21 (purified extracted saponin), and Sorensen's...” NCT05500417 ↗ |
| Route | Intramuscular | “Each subject will receive a 1 mL intramuscular (IM) injection containing 1 microgram of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) and a full dose of Army Liposome...” NCT05500417 ↗ |